5月7日 - ** Atara Biotherapeutics ATRA.O 股价上涨43%，至7.39美元
** 该公司与美国食品药品监督管理局（FDA）会面，商讨如何重启其抗癌药物塔贝克鲁塞尔（tabelecleucel）的申请
** Atara表示，FDA同意一项包含历史对照组的单臂研究足以支持新的申请
** 监管机构于1月拒绝批准 (link) 的塔贝克鲁塞尔（tabelecleucel），这是继此前因生产检查问题驳回该疗法后，第二次遭到拒绝
** 合作伙伴皮埃尔·法布尔制药公司计划重新提交申请，其中将包含来自其晚期临床试验的最新患者数据及更长的随访期
** Atara预计将在第三季度发布进一步的监管进展
** 今年以来股价累计下跌71%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.